Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report report published on Monday. The firm issued a hold rating on the stock.

A number of other brokerages have also recently weighed in on ONCT. Northland Securities restated a market perform rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright cut their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research report on Monday, August 12th. Brookline Capital Management reiterated a hold rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk cut Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Oncternal Therapeutics has an average rating of Hold and a consensus price target of $20.00.

Oncternal Therapeutics Stock Up 11.5 %

NASDAQ:ONCT opened at $1.65 on Monday. Oncternal Therapeutics has a 52 week low of $1.32 and a 52 week high of $13.14. The stock’s fifty day moving average is $5.02 and its two-hundred day moving average is $7.29. The stock has a market capitalization of $4.88 million, a price-to-earnings ratio of -0.13 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same quarter in the prior year, the company earned ($3.00) EPS. On average, sell-side analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors and hedge funds.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.